Jeffrey Rubasingham News Today

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated

January 23, 2023

Data presented at the European Symposium on Ultrasound Contrast Imaging also demonstrated consistent SonoTran® Particle activationRecruitment underway for Delivery and Efficacy cohorts of Phase 1/2a proof of concept studyOXFORD, UK, January 23, 2023 / B3C newswire / -- OxSonics Therapeutics, a clinical-stage medtech...

United Kingdom Marianna Lalla Jeffrey Rubasingham Stephanie Cuthbert Phillip Oxford Cancer Centre University Of Oxford

Source: pharmiweb.com

Navigation

Jeffrey Rubasingham News Today

OxSonics trial produces positive SonoTran data

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated

Explore More Categories

Navigation

Jeffrey Rubasingham News Today

OxSonics trial produces positive SonoTran data

First-in-Human Clinical Data Shows SonoTran&#xAE; is Safe and Well-Tolerated

Explore More Categories

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated